E 
Eurofins Scientific ERF.PA · EUR
Health Care · Life Sciences Tools & Services · Euronext Paris · 🇫🇷 France
87.24
-1.58%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in EUR, from our data supplier.
Revenue
€7.30bn
FY2016FY2025
Net income
€475.0m
FY2016FY2025
Free cash flow
€535.0m
FY2016FY2025
Shareholders' equity
€3.54bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | €7.30bn | €6.95bn | €6.51bn | €6.71bn | €6.72bn | €5.44bn | €4.56bn | €3.78bn | €2.97bn | €2.54bn |
| Operating income | €818.3m | €726.2m | €546.8m | €783.2m | €1.28bn | €906.3m | €421.9m | €355.8m | €303.1m | €281.9m |
| Net income | €475.0m | €406.4m | €310.3m | €610.2m | €782.6m | €539.4m | €195.2m | €223.9m | €216.8m | €174.0m |
| Diluted earnings per share | 2.54 | 2.10 | 1.57 | 3.08 | 3.91 | 2.74 | 1.05 | 1.24 | 1.20 | 0.99 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | €10.98bn | €10.89bn | €10.89bn | €10.08bn | €9.33bn | €8.58bn | €7.82bn | €7.21bn | €5.83bn | €4.13bn |
| Cash and short-term investments | €791.0m | €613.9m | €1.22bn | €486.6m | €515.3m | €912.4m | €297.0m | €506.2m | €820.4m | €826.1m |
| Total liabilities | €7.40bn | €5.50bn | €5.75bn | €5.23bn | €4.66bn | €4.86bn | €4.92bn | €4.48bn | €3.35bn | €2.37bn |
| Debt | €4.43bn | €3.61bn | €3.93bn | €3.33bn | €2.75bn | €3.15bn | €3.54bn | €3.16bn | €2.22bn | €1.38bn |
| Shareholders' equity | €3.54bn | €5.34bn | €5.08bn | €4.78bn | €4.65bn | €3.69bn | €2.84bn | €2.67bn | €2.44bn | €1.63bn |
| Shares outstanding | 187m | 194m | 198m | 198m | 200m | 197m | 186m | 180m | 181m | 175m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | €1.29bn | €1.32bn | €1.02bn | €1.14bn | €1.51bn | €1.22bn | €677.9m | €543.9m | €405.1m | €371.8m |
| Capital spending | −€760.0m | −€528.4m | −€550.1m | −€660.2m | −€519.5m | −€355.5m | −€425.1m | −€364.4m | −€245.7m | −€199.7m |
| Free cash flow | €535.0m | €790.5m | €467.8m | €476.1m | €990.3m | €868.0m | €252.8m | €179.4m | €159.4m | €172.2m |
| Dividends paid | −€110.0m | −€95.6m | −€191.9m | −€192.5m | −€130.4m | −€500,000 | −€51.4m | −€42.6m | −€34.9m | −€22.5m |
Latest quarters
By quarter end
| Jun 2026 | Dec 2025 | Jun 2025 | Dec 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sept 2023 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | €3.70bn | €3.68bn | €3.61bn | €3.53bn | €3.42bn | €1.71bn | €3.31bn | €1.65bn |
| Operating income | €499.0m | €385.1m | €754.4m | €351.7m | €374.5m | €219.7m | €279.9m | €190.3m |
| Net income | €302.0m | €228.4m | €246.6m | €185.7m | €220.7m | €97.0m | €158.8m | €65.9m |
| Diluted earnings per share | 1.64 | 1.22 | 1.32 | 0.96 | 1.14 | 0.50 | 0.80 | 0.33 |
| Cash from operations | €575.0m | €789.0m | €505.0m | €709.0m | €514.0m | €265.0m | €627.0m | €342.0m |
| Capital spending | −€191.0m | −€538.0m | −€110.0m | −€236.0m | −€217.0m | −€108.0m | −€287.0m | −€125.0m |
| Free cash flow | €384.0m | €251.0m | €395.0m | €473.0m | €297.0m | €157.0m | €340.0m | €217.0m |
| Total assets | €11.11bn | €10.98bn | €10.59bn | €10.89bn | €10.80bn | €10.80bn | €10.89bn | €10.89bn |
| Cash and short-term investments | €618.0m | €791.0m | €753.3m | €613.9m | €681.2m | €681.2m | €1.22bn | €1.23bn |
| Debt | €772.0m | €4.43bn | €4.11bn | €3.61bn | €3.54bn | €23.4m | €3.49bn | €458.4m |
| Shareholders' equity | €3.62bn | €3.54bn | €4.64bn | €5.34bn | €5.24bn | €5.24bn | €4.08bn | €5.08bn |
Financial ratios
Data as of 3 Oct 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Operating margin | 11.2% | 10.4% | 8.4% | 11.7% | 19.0% | 16.7% |
| Net margin | 6.5% | 5.8% | 4.8% | 9.1% | 11.6% | 9.9% |
| Return on equity | 13.4% | 7.6% | 6.1% | 12.8% | 16.8% | 14.6% |
| Return on assets | 4.3% | 3.7% | 2.8% | 6.1% | 8.4% | 6.3% |
| Free cash flow yield | 14.7% | 12.7% | 10.6% | 12.1% | 13.5% | 10.7% |
| Revenue growth | 5.0% | 6.7% | -2.9% | -0.1% | 23.5% | 19.2% |
| Earnings growth | 16.9% | 31.0% | -49.1% | -22.0% | 45.1% | 176.3% |
| Current ratio | 1.09x | 1.16x | 1.45x | 1.31x | 1.25x | 1.48x |
| Debt to equity | 1.17x | 0.59x | 0.69x | 0.61x | 0.50x | 0.74x |
| Equity ratio | 32.3% | 49.0% | 46.6% | 47.4% | 49.8% | 43.0% |
| Interest coverage | 4.93x | 4.82x | 4.23x | 7.42x | 7.39x | 8.75x |
| Buybacks as a share of market value | 3.4% | 2.0% | 0.2% | 1.1% | -1.6% | -5.9% |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 2.8% | 6.1% | 14.1% |
| Operating income | 1.5% | -2.0% | 20.0% |
| Net income | -8.0% | -2.5% | 18.5% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Operating margin | 10.8% | 10.5% | 12.8% | 11.8% |
| Net margin | 6.2% | 6.6% | 7.9% | 7.3% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 24.5 | 23.5 | 37.6 | 21.8 | 27.8 | 25.1 | 47.1 | 26.2 | 42.5 | 40.8 |
| Price to sales | 1.6 | 1.4 | 1.8 | 2.0 | 3.2 | 2.5 | 2.0 | 1.6 | 3.1 | 2.8 |
Dividends and splits
Per share, in the currency the company pays
Paid for 5 years. Last went ex-dividend on 28 Apr 2026.
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Paid in the year | 0.72 | 0.60 | 0.50 | 1.00 | 1.00 | 0.68 | 0.288 | 0.24 |
- 10-for-1 split · 19 Nov 2020
- 10-for-1 split · 22 May 2000
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.